Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
4.760
-0.030 (-0.63%)
Jun 26, 2025, 4:00 PM - Market closed
Avalo Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| 0.44 | 0.44 | 1.92 | 18.05 | 5.4 | 6.7 | Upgrade
| |
Revenue Growth (YoY) | -69.56% | -77.08% | -89.34% | 234.40% | -19.42% | -0.76% | Upgrade
|
Cost of Revenue | 20.8 | 15.28 | 9.95 | 25.99 | 50.12 | 25.24 | Upgrade
|
Gross Profit | -20.36 | -14.84 | -8.02 | -7.94 | -44.72 | -18.54 | Upgrade
|
Selling, General & Admin | 19.59 | 17.24 | 10.3 | 13.91 | 24.66 | 19.76 | Upgrade
|
Research & Development | 10.36 | 8.8 | 5.12 | 8.05 | 11.21 | 7.26 | Upgrade
|
Operating Expenses | 29.95 | 26.04 | 15.42 | 22 | 37.41 | 28.76 | Upgrade
|
Operating Income | -50.31 | -40.87 | -23.44 | -29.94 | -82.13 | -47.29 | Upgrade
|
Interest Expense | - | - | -3.42 | -4.17 | -2.39 | - | Upgrade
|
Interest & Investment Income | 4.37 | 3.32 | - | - | - | 0.05 | Upgrade
|
Other Non Operating Income (Expenses) | 119.18 | 30.18 | -0.76 | -0.02 | -0.02 | 0.41 | Upgrade
|
EBT Excluding Unusual Items | 73.23 | -7.37 | -27.62 | -34.13 | -84.55 | -46.84 | Upgrade
|
Merger & Restructuring Charges | - | - | - | -7.5 | - | - | Upgrade
|
Impairment of Goodwill | - | - | -3.91 | - | - | - | Upgrade
|
Gain (Loss) on Sale of Investments | - | - | - | - | - | 5.21 | Upgrade
|
Pretax Income | 73.13 | -35.02 | -31.53 | -41.63 | -84.55 | -67.18 | Upgrade
|
Income Tax Expense | 0.12 | 0.11 | 0.01 | 0.03 | -0.2 | -2.79 | Upgrade
|
Earnings From Continuing Operations | 73.01 | -35.13 | -31.54 | -41.66 | -84.35 | -64.38 | Upgrade
|
Earnings From Discontinued Operations | - | - | - | - | -0.03 | 0.88 | Upgrade
|
Net Income | 73.01 | -35.13 | -31.54 | -41.66 | -84.38 | -63.5 | Upgrade
|
Net Income to Common | 73.01 | -35.13 | -31.54 | -41.66 | -84.38 | -63.5 | Upgrade
|
Shares Outstanding (Basic) | 7 | 4 | 0 | 0 | 0 | 0 | Upgrade
|
Shares Outstanding (Diluted) | 10 | 7 | 0 | 0 | 0 | 0 | Upgrade
|
Shares Change (YoY) | 1963.09% | 2599.19% | 608.45% | 8.32% | 41.86% | 28.52% | Upgrade
|
EPS (Basic) | 10.67 | -7.94 | -113.58 | -1062.65 | -2331.41 | -2489.12 | Upgrade
|
EPS (Diluted) | -4.90 | -20.91 | -113.58 | -1062.65 | -2331.41 | -2489.12 | Upgrade
|
Free Cash Flow | -52.31 | -49.06 | -30.84 | -26.85 | -71.01 | -40.6 | Upgrade
|
Free Cash Flow Per Share | -5.28 | -6.54 | -111.04 | -684.81 | -1961.95 | -1591.55 | Upgrade
|
Gross Margin | - | - | - | -43.98% | - | -276.70% | Upgrade
|
Operating Margin | -11408.39% | -9267.80% | -1218.50% | -165.86% | -1521.56% | -705.99% | Upgrade
|
Profit Margin | 16556.01% | -7965.76% | -1639.50% | -230.78% | -1563.10% | -947.90% | Upgrade
|
Free Cash Flow Margin | -11861.91% | -11123.81% | -1602.81% | -148.72% | -1315.39% | -606.09% | Upgrade
|
EBITDA | -50.04 | -40.7 | -23.29 | -29.77 | -80.48 | -45.45 | Upgrade
|
EBITDA Margin | - | - | - | -164.94% | - | - | Upgrade
|
D&A For EBITDA | 0.27 | 0.17 | 0.16 | 0.17 | 1.66 | 1.84 | Upgrade
|
EBIT | -50.31 | -40.87 | -23.44 | -29.94 | -82.13 | -47.29 | Upgrade
|
EBIT Margin | - | - | - | -165.86% | - | - | Upgrade
|
Effective Tax Rate | 0.16% | - | - | - | - | - | Upgrade
|
Revenue as Reported | 0.44 | 0.44 | 1.92 | 18.05 | 5.4 | 6.7 | Upgrade
|
Updated Mar 20, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.